NVCT
NVCT
NASDAQ · Biotechnology

Nuvectis Pharma Inc

$7.82
+0.09 (+1.16%)
As of Apr 1, 2:30 PM ET ·
Financial Highlights (FY 2025)
Revenue
66.09M
Net Income
7.65M
Gross Margin
63.9%
Profit Margin
11.6%
Rev Growth
+12.3%
D/E Ratio
0.76
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 63.9% 63.9% 63.9%
Operating Margin 14.5% 13.0% 13.1%
Profit Margin 11.6% 14.0% 15.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 66.09M 69.56M 73.83M
Gross Profit 42.26M 44.47M 47.20M
Operating Income 9.61M 9.02M 9.70M
Net Income 7.65M 9.76M 11.38M
Gross Margin 63.9% 63.9% 63.9%
Operating Margin 14.5% 13.0% 13.1%
Profit Margin 11.6% 14.0% 15.4%
Rev Growth +12.3% +24.1% -0.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 97.76M 88.37M 98.46M
Total Equity 128.28M 136.69M 131.71M
D/E Ratio 0.76 0.65 0.75
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 12.79M 14.57M 15.15M
Free Cash Flow 6.98M 8.54M 10.02M